RNA Covid vaccine was initially 'developed for oncology use and was already in phase 2'

FRANCE 24 English 2025-06-05

Views 2


Visit our website:
http://www.france24.com

Like us on Facebook:
https://www.facebook.com/FRANCE24.English

Follow us on Twitter:
https://twitter.com/France24_en
Show more

Share This Video


Download

  
Report form
RELATED VIDEOS
Testing begins on two new COVID vaccines developed by Melbourne researchers
play
03:05

Testing begins on two new COVID vaccines developed by Melbourne researchers
JSB Market Research: Veterinary Vaccines and Animal Vaccines Market, Diseases, Technology - Global Forecast to 2018
play
00:15

JSB Market Research: Veterinary Vaccines and Animal Vaccines Market, Diseases, Technology - Global Forecast to 2018
Messenger RNA vaccines
play
01:48

Messenger RNA vaccines
Messenger RNA vaccines
play
01:48

Messenger RNA vaccines
Vaccine research: Drug companies developing vaccines to fight new strains
play
01:28

Vaccine research: Drug companies developing vaccines to fight new strains
Why questions are being raised on indigenous developed vaccines
play
23:52

Why questions are being raised on indigenous developed vaccines
Vaccines being developed to protect against Omicron
play
02:53

Vaccines being developed to protect against Omicron
#PTVNewsTonight | More than 200 vaccines being developed worldwide
play
02:07

#PTVNewsTonight | More than 200 vaccines being developed worldwide
WHO hopeful COVID-19 vaccines could be developed before end of 2020
play
00:40

WHO hopeful COVID-19 vaccines could be developed before end of 2020
ICMR says both vaccines developed in India are safe
play
02:59

ICMR says both vaccines developed in India are safe
Brazil raises questions over transparency in authorization of COVID-19 vaccines developed by China
play
00:44

Brazil raises questions over transparency in authorization of COVID-19 vaccines developed by China
Vaccines have been developed for cancer patients that have 'high-risk of recurrence'
play
04:49

Vaccines have been developed for cancer patients that have 'high-risk of recurrence'